Premium
N ‐Acetylcysteine Use for Amelioration of Aminoglycoside‐Induced Ototoxicity in Dialysis Patients
Author(s) -
Feldman Leonid,
Sherman Richard A.,
Weissgarten Joshua
Publication year - 2012
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.2012.01090.x
Subject(s) - ototoxicity , medicine , aminoglycoside , dialysis , acetylcysteine , gentamicin , antibiotics , intensive care medicine , hearing loss , population , pharmacology , antioxidant , chemotherapy , audiology , biochemistry , chemistry , microbiology and biotechnology , environmental health , cisplatin , biology
Use of aminoglycoside antibiotics is associated with significant ototoxicity, especially on patients with decreased renal function. The risk of aminoglycoside ototoxicity may approach 60%. Oxidative stress has been suggested as a general mechanism of aminoglycoside ototoxicity and is prevalent in dialysis population. N ‐acetylcysteine (NAC) is an effective antioxidant and has been safely used in dialysis patients. New experimental and clinical data, explored in this review, provide a good case to recommend NAC administration to all dialysis patients, receiving aminoglycosides.